Skepta and PUMA Launch Groundbreaking Collection 
McDonald's Faces Backlash Over $5 Meal Deal: Customers Call It 'Skimpy' 
Lapstone & Hammer Expands ASICS 'Dip Dye' Series with Beverage-Inspired Colorways 
Dolly Parton Serves Up Sweetness with Krispy Kreme Collaboration 
Coca-Cola Launches Lens Platform to Offer Key Data for Retail and Foodservice 
Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
McDonald's China Faces Backlash for Food Hygiene Violations 
ECB Calls for Monitoring and Possible Regulation of AI in Finance 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
ALWAYTH x Adidas Samba: Revolutionizing Sneaker Culture with Fashion-Forward Collaboration 
Burger King’s Largest Franchisee Carrols, Acquired by RBI for $1 Billion, $500M Revamp 
Why banks consider renewable energy to be a riskier investment than fossil fuels 
McDonald's Philippines Launches 'Ride the Arches' for Cyclists 
STAMFORD, Conn., Aug. 03, 2017 -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the Canaccord Genuity 37th Annual Growth Conference on Thursday, August 10, 2017, at 8:00 a.m. ET in Boston.
A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body's peripheral nervous system. CR845 has demonstrated initial efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. In patients with moderate-to-severe CKD-associated pruritus, CR845 has demonstrated its potential to reduce itch and improve quality of life.
INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations, Inc. 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
